Homeopathic Drug Product Safety, Quality, and Transparency Act

This bill creates a separate set of federal rules for homeopathic drug products under the Federal Food, Drug, and Cosmetic Act. It bars the FDA from requiring premarket approval for these products and sets manufacturing and safety standards based mainly on the Homeopathic Pharmacopoeia of the United States or accredited consensus standards. Retail products must list uses for self-limiting conditions backed by listed sources, along with a statement that the FDA has not evaluated those uses. The bill creates a 10-member Homeopathic Drug Product Advisory Committee, limits certain false-advertising claims against compliant products, and cancels a 2022 FDA guidance on homeopathic drugs.

Full text and official record on Congress.gov

Sponsors

• Pete Sessions Republican sponsor
• 6 cosponsors